Bened Biomedical Grants Exclusive Rights for PS128™ to M8 Pharmaceuticals
Retrieved on:
Tuesday, December 8, 2020
The agreement focused on Brazil & Mexico secures M8 exclusive rights to market PS128, a psychobiotic with several completed as well as ongoing clinical studies, for mental and neurological disorders.
Key Points:
- The agreement focused on Brazil & Mexico secures M8 exclusive rights to market PS128, a psychobiotic with several completed as well as ongoing clinical studies, for mental and neurological disorders.
- The region is one of the high potential emerging markets identified for Bened Biomedical to expand its global presence with its unique psychobiotics portfolio.
- Joel Barlan, CEO of M8 said: "We are delighted to partner with Bened to bring a novel psychobiotic to market.
- Bened Biomedical Co., Ltd. was founded in 2015 in Taipei, Taiwan, as a spin-out company from National Yang-Ming University (NYMU).